# Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects

> **NCT02559258** · PHASE1 · TERMINATED · sponsor: **Tunitas Therapeutics, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Allergy and Immunology

## Interventions

- **DRUG:** 0.1 mg/kg epsi-gam or placebo (6:2)
- **DRUG:** 0.3 mg/kg epsi-gam or placebo (6:2)
- **DRUG:** 1.0 mg/kg epsi-gam or placebo (6:2)
- **DRUG:** 3 mg/kg epsi-gam or placebo (6:2)
- **DRUG:** 10 mg/kg epsi-gam or placebo (6:2)

## Key facts

- **NCT ID:** NCT02559258
- **Lead sponsor:** Tunitas Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2016-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02559258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02559258, "Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02559258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*